Hongbo Pharmaceutical (301230.SZ) announced that Jiang Shengli, the company's director and board secretary, recently received a Chinese certificate...
Zhitong Finance App News, Hongbo Pharmaceutical (301230.SZ) announced that Jiang Shengli, the company's director and board secretary, recently received [2024] No. 128 “Decision on Measures to Issue a Warning Letter against Jiang Shengli” issued by the Shanghai Regulatory Bureau (“Shanghai Securities Regulatory Bureau”) of the China Securities Regulatory Commission.
After investigation, Jiang Shengli, as a director of the company and secretary of the board of directors, bought 14,000 shares of the company's shares on January 31, 2024, with a transaction amount of 396,600 yuan, and sold 14,000 shares of the company's shares on March 13, 2024, for a transaction amount of 509,600 yuan. The above acts constituted a short-term transaction, and the Shanghai Securities Regulatory Bureau decided to take administrative supervision measures to issue a warning letter against Jiang Shengli.